CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 29 enrolled
Drug / intervention
AN2690 Solution, 5.0%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01278394
NCT01278394Phase 2Completed
CompareCT.gov

An Open-Label, Rising Multiple-Dose, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 5.0% and 7.5% Solution for the Treatment of Adult Subjects With Onychomycosis of the Great Toenail

Pfizer·interventional·Posted Jan 17, 2011·Updated Dec 6, 2018

In Brief

A Phase 2 clinical trial evaluating AN2690 Solution, 5.0% for Onychomycosis. Completed, enrolled 29 participants across 2 sites.

Detailed Summary

The purpose of the study is to determine the safety and efficacy of 5.0% AN2690 Solution in the treatment of distal, subungual onychomycosis of the great target toenail.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOnychomycosis
CountriesMexico
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 17, 2011
Enrollment StartMar 1, 2007
Primary CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 15.5 years ago

Interventions

AN2690 Solution, 5.0%drug

Once daily application for 360 days